DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Oncology Homepage

Robotic-assisted transhiatal esophagectomy is safe and effective for certain patients But it's a complex procedure to perform

Margarita Valdez American Society for Radiation oncology hires new assistant director of congressional relations

J. Michael Bruff Varian announces new VP of Investor Relations

Louisiana hospitals deploy Synaptive's BrightMatter technology Builds on earlier investments in neuroscience

Varian to market Bionix brachytherapy applicators in North America Two tools for treating upper GI and anal/rectal cancers

Accuray’s TomoTherapy more effective than Varian’s RapidArc, non-randomized study finds French study examined outcomes for 166 patients

Cancer patient in Italy first to undergo Varian HyperArc radiotherapy Delivers compact radiation doses to tumors with improved targeting

New PET tracer for prostate cancer shows benefits over current standard: study 11C-sarcosine could also be used for other cancers

Praveen Dalmia Karmanos Cancer Institute appoints new corporate director of Oncology Technology & Innovation

Study finds majority of insurance denials overturned in pediatric proton patients Policy language may need revising

Courtesy of Dr. Neeta Pandit-Taskar
and Dr. Michael J. Morris

New PET imaging agent detects metastatic prostate cancer

by Lauren Dubinsky , Senior Reporter
Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of The Journal of Nuclear Medicine.

With an estimated 1.1 million new cases and over 300,000 deaths annually from prostate cancer, it is the second most common cancer among men globally, according to the World Health Organization.

Story Continues Below Advertisement

InfoView - Asset management simplified

Now, there's a powerful asset management tool that helps you effectively manage, monitor and control your clinical assets with improved financial and operational performance. InfoView - helping hospitals make better decisions. Click to learn more>>>



X-ray, CT and MR are traditionally used to determine if prostate cancer has spread to other areas of the body, but it’s often a challenge to image. With this new molecular imaging approach, researchers have shown they can target both bone and soft tissue lesions.

The radiotracer combines a small amount of the radioactive material zirconium-89 with a fragment of an antibody called a minibody. The minibody has anti-prostate-specific membrane antigen qualities that cause it to attach to prostate cancer cells that traveled in the body.

PET then detects the particles that are emitted from the site and the resulting image shows the "hot spots" of PSMA overexpression. This method can detect prostate cancer cells that have metastasized to bone, which is the most difficult to find with standard approaches.

For the study, the researchers imaged 18 patients with new imaging agent, using PET/CT. They also conducted CT, MR, molecular bone and FDG-PET exams and then selected and biopsied the suspected disease sites.

They found the Zr-89-Df-IAB2M PET scans were positive in 17 of the patients with bone lesions found in nine and soft tissue disease found in 14.

The bone scans conducted with Tc-99m-methylene diphosphonate and FDG were positive for bone lesions in nine and six patients, respectively. CT and FDG scans were positive for soft tissue disease in 14 and 10 patients, respectively.

In two of the patients, a single site of disease in each patient was found only by Zr-89-Df-IAB2M. In total, the new agent detected 147 bone and 82 soft tissue lesions.

The researchers are hoping that once this approach is further developed, it will help to detect metastatic prostate cancer earlier and more accurately. They believe that after further validation, the agent may be used for targeted biopsies and even targeted radiotherapy.

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED